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Translational Relevance 
Emerging data suggests that DNA damage repair (DDR) gene mutations may be 
predictive of response to platinum-based chemotherapy in some cancers however, the 
role of these mutations in pancreatic adenocarcinoma (PDAC) is unknown. 
FOLFIRINOX (5-Fluorouracil, leucovorin, irinotecan and oxaliplatin) is a platinum-based 
chemotherapeutic regimen that is commonly used as first-line treatment of patients with 
advanced PDAC. However, the efficacy of FOLFIRINOX is limited by its high toxicities 
and low objective response rate. Currently, there is no predictive biomarker to select 
patients for treatment with FOLFIRINOX. In this study, we report that the presence of 
DDR gene mutations is associated with improved OS in metastatic PDAC patients 
treated with FOLFIRINOX. These results will need to be further tested in a larger study 
and may serve to select PDAC patients for treatment with FOLFIRINOX.  
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Abstract 
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with lack of 
predictive biomarkers. We conducted a study to assess DNA damage repair (DDR) 
gene mutations as a predictive biomarker in PDAC patients treated with FOLFIRINOX. 
Experimental Design: Indiana University Simon Cancer Center pancreatic cancer 
database was used to identify patients with metastatic PDAC, treated with FOLFIRINOX 
and had tissue available for DNA sequencing. Baseline demographic, clinical and 
pathologic information was gathered. DNA isolation and targeted sequencing was 
performed using the Ion AmpliSeq protocol. Overall survival (OS) analyses was 
conducted using Kaplan-Meier, logistic regression and Cox proportional hazard 
methods. Multivariate models were adjusted for age, gender, margin status, CA 19-9, 
adjuvant chemotherapy, tumor and nodal stage. 
Results: Overall, 36 patients were sequenced. DDR gene mutations were found in 12 
patients. Mutations were seen in BRCA1 (N=7), BRCA2 (N=5), PALB2 (N=3), MSH2 
(N=1) and FANCF (N=1) of all the DDR genes sequenced. Median age was 65.5 years, 
58% were male, 97.2% were Caucasian and 51.4% had any family history of cancer. 
The median OS was near significantly superior in those with DDR gene mutations 
present vs. absent (14 vs. 5 months; HR 0.58 [0.29-1.14], log-rank p=0.08). Multivariate 
logistic (OR 1.47 [1.04-2.06], p = 0.04) and Cox regression (HR 0.37 [0.15-0.94], p = 
0.04) showed presence of DDR gene mutations was associated with improved OS.  
Conclusion: In a single institution, retrospective study, we found that the presence of 
DDR gene mutations are associated with improved OS in PDAC patients treated with 
FOLFIRINOX. 
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Introduction 
Pancreatic ductal adenocarcinoma (PDAC) remains a lethal cancer with a 5-year 
survival rate of less than 5% overall1 and 15-20% for early stage resectable disease2. 
Moreover, PDAC is projected to become the second leading cause of cancer mortality 
in the United States within a decade3. Genome stability is compromised in all cancers 
including PDAC and can be broadly categorized into chromosomal instability (CIN) and 
microsatellite instability (MIN)4, 5. The spectrum of altered genes, as well as the types of 
alterations, makes each PDAC rather distinctive. These alterations can be divided into 
required (nearly universally seen; such as, KRAS and CDKN2A), frequently mutated 
(occurring in more than 25% of tumors; such as, SMAD4, TP53, and NCOA3) and low 
frequency mutations (occurring in less than 25% of tumors; such as RB1, BRCA2 and 
ERBB2)5, 6.  Low frequency mutations, including mutations in DNA damage repair 
(DDR) pathways, provide a very heterogeneous mutational background that gives each 
PDAC a unique molecular signature.   
DDR pathways play an important role in the cellular response to platinum 
chemotherapy. FOLFIRINOX (5-Fluorouracil, leucovorin, irinotecan and oxaliplatin) is a 
platinum based chemotherapeutic regimen that has shown an unprecedented 
improvement in median overall survival (OS) to 11.1 months7. However, not all PDAC 
patients respond to FOLFIRINOX chemotherapy; objective response rate is around 
32%7. Chemotherapy resistance mechanisms are multifactorial, but  alterations in DDR 
pathways such as nucleotide excision repair (NER), mismatch repair (MMR), and BRCA 
pathways8 likely contribute significantly. For example, the excision repair cross-
complementation group 1 (ERCC1) protein is a key component of nucleotide excision 
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repair pathway. High expression of ERCC1 has been associated in multiple studies with 
acquired or intrinsic resistance to platinum drugs8, 9. Similarly, loss or loss of function of 
MMR genes (mainly MLH1 and MSH2) has been associated with resistance to platinum 
compounds10. Lastly, BRCA1 and BRCA2 genes have established roles in DNA repair 
and chemotherapy sensitivity11, 12. However, these data come from either preclinical 
studies or clinical studies done in other cancer types and the role of DDR pathway gene 
alterations on the efficacy of FOLFIRINOX in pancreatic cancer is not well known.  
The primary objective of this study was to assess the effect of mutations in DDR 
genes (BRCA1, BRCA2, PALB2, CHEK1, CHEK2, RAD51, MLH1, MSH2, ERCC1, 
ERCC4, PARP1, FANCF, ATR and MDC1) on the OS of patients with metastatic PDAC 
treated with FOLFIRINOX.  
Methods and Materials 
Study Population and Patient selection 
Patients were selected from the Indiana University Simon Cancer Center 
pancreatic cancer database, which is a large Institutional review board (IRB) approved 
high quality prospective and retrospective data collection repository13. The main 
inclusion criterion (to allow for adequate available tissue) for the study was histologic 
diagnosis of recurrent pancreatic adenocarcinoma.  Patients must have been treated 
after recurrence with FOLFIRINOX (in the first-line setting) and had available formalin-
fixed paraffin embedded tissue for DNA sequencing. The individuals who met the 
inclusion criteria formed the final cohort for the study and underwent DNA sequencing. 
The study was approved by the institutional IRB with a waiver for informed consent. 
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This was mainly because of the retrospective nature of the study and the fact that most 
patients had died at the time of study conception. The study was conducted in 
accordance with recognized ethical guidelines (Declaration of Helsinki, Belmont Report 
and U. S. Common Rule). 
Data Collection 
Baseline demographic, clinical and pathologic information including age at 
diagnosis, gender, race, family history of any cancer, location of primary tumor, Eastern 
Cooperative Oncology Group (ECOG) performance status, body mass index (BMI), 
baseline carbohydrate antigen 19-9 (CA 19-9), history of surgical resection, type of 
surgical resection (R0 or R1), adjuvant chemotherapy, pathological tumor and nodal 
stage were collected. The start date of FOLFIRINOX and date of death were collected 
for OS calculation. 
DNA-Extraction 
Matched tumor-normal paired tissue sections with ≥ 20% tumor cellularity were 
selected for DNA isolation. The sections were scraped from glass slides using 
microtome blades and the QIAamp DNA FFPE Tissue Kit (56404, Qiagen) was used for 
DNA isolation.  
Next Generation Sequencing for Germline and Somatic Mutations 
Germline mutation testing was done using adjacent normal tissue whereas 
somatic mutation testing was done using tumor tissue. Sequencing libraries were 
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constructed using the Ion AmpliSeq Kit for Chef DL8 (A29024, Thermo Scientific) in 
conjunction with the Ion Comprehensive Cancer Panel Primer Pool (4477685, Thermo 
Scientific).  Templates were prepared on the Ion Chef using the Ion P1 Hi-Q Chef Kit 
(A27198, Thermo Scientific).  Templates were sequenced to at least 500X mean 
coverage on the Ion Proton sequencer using a P1 Chip v3 (A26771, Thermo Scientific). 
Genomic data (BAM files) were uploaded to Ion Reporter (Thermo Scientific) for 
somatic variant and copy number calling.  Ingenuity Variant Analysis (Qiagen) was also 
used for second-level annotation. 
Statistical analyses 
Descriptive statistics were used to summarize the baseline characteristics and 
mutations in DDR genes (BRCA1, BRCA2, PALB2, CHEK1, CHEK2, RAD51, MLH1, 
MSH2, ERCC1, ERCC4, PARP1, FANCF, ATR and MDC1). The study cohort was then 
divided in to those with and without germline and somatic mutations in DDR genes. 
Baseline characteristics were compared between the two groups (DDR gene mutations 
present vs. absent) using chi-square test for categorical variables and Student t-test for 
continuous variables.  
Two statistical approaches were used for data analyses. First, we analyzed the 
data using logistic regression analysis as in a case-control study to investigate the 
association between DDR gene mutations and OS (categorized as above and below 3rd 
quartile). Our goal here was to see if PDAC patients with DDR gene mutations had 
higher odds of being in the highest quartile for OS. The cases were defined as PDAC 
patients with mutations in these genes and the controls were those without mutations. 
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The multivariate logistic regression analysis was adjusted for age at diagnosis, gender, 
margin status, CA 19-9 level, adjuvant chemotherapy, pathological T and N stage. 
Adjusted odds ratios (AORs) were reported along with 95% confidence intervals (CI).  
Second, we conducted time-to-event analysis with the event being OS. OS was 
defined as the time from the start of chemotherapy with FOLFIRINOX to the time of 
death or last follow up. The Kaplan-Meier method was used for estimating OS. OS 
between those with and without mutations in DDR genes was compared by log-rank 
test. A Cox proportional hazard regression model was used to calculate hazard ratios 
(HR) and 95% CI while adjusting for other covariates (same variables as for multivariate 
logistic regression analysis) between the two groups (DDR gene mutation present or 
absent). We also conducted an analysis with ‘OS from surgery’ to understand if the 
differences of OS in patients with and without DDR gene mutations were irrespective of 
the treatment with FOLFIRINOX. The ‘OS from surgery’ was defined as the time interval 
from the date of surgery to the date of death or last follow up. 
Lastly, we also conducted a sensitivity analysis where we assessed the role of 
only BRCA1 and BRCA2 (BRCA1/2) mutations (instead of DDR gene mutations) on OS 
using the logistic and Cox regression models while adjusting for other covariates. For 
this study, p  0.05 was considered statistically significant and 0.05 < p  0.10 was 
considered near significant. Data management and statistical analysis was performed 
with R 1.1.42314. 
Results 
Patient characteristics 
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There were 47 PDAC patients in the entire cohort who received platinum-based 
chemotherapy with FOLFIRINOX in the first-line metastatic setting. Of these 47 
patients, 11 patients were excluded either due to inability to locate the tissue blocks 
(N=9) or due to low tumor cellularity (N=2). Thus, there were 36 PDAC patients in the 
final cohort that received FOLFIRINOX. All the patients had previously undergone 
curative intent resection of their PDAC. Baseline characteristics are summarized in 
Table 1. The median age for the entire cohort was 65.5 years (range 45.1-82.7 years), 
58% were male, and the majority (97.2%) were Caucasian. Family history of any cancer 
was noted in 51.4% of the patients. Most patients (86.1%) had received postoperative 
adjuvant chemotherapy with gemcitabine. 
DNA Damage Repair Gene Mutations 
DDR gene mutations were found in 12 (33.3%) patients in our cohort. BRCA1, 
BRCA2, PALB2, MSH2 and FANCF genes were mutated in 7 (19.4%), 5 (13.9%), 3 
(8.3%), 1 (2.8%) and 1 (2.8%) patients respectively (Table 2). There were no mutations 
(germline or somatic) seen in other DDR genes (CHEK1, CHEK2, RAD51, MLH1, 
ERCC1, ERCC4, PARP1, ATR and MDC1). Nine (25%) patients had one or more 
BRCA1/2 mutation. Both BRCA1 and BRCA2 were mutated in 3 (8.3%) of these 
patients. The details of specific mutations seen in DDR genes is summarized in Table 2. 
Besides relatively younger age at diagnosis in those with DDR gene mutations (64.6 vs. 
66.0 years respectively, p = 0.002), there were no significant demographic or clinical 
differences between those with and without mutations in DDR genes (Table 1).  
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DNA Damage Repair Gene Mutations and Overall Survival 
The median OS for the entire cohort was 6 months (range 1-24 months). The first 
and third quartile were 3 and 14 months respectively. Eight (25%) patients had OS 
above the third quartile. Bivariate logistic regression showed that the patients with 
mutations in DDR genes had higher odds of being in the highest quartile of OS (OR 
1.34, 95% CI 1.01-1.77, p = 0.05). This association remained significant after adjusting 
for other potential prognostic variables in a multivariate logistic regression model (AOR 
1.47, 95% CI 1.04-2.06, p = 0.04; Table 3). Interestingly, multivariate analysis did not 
reveal any other variables that were significantly associated with the highest quartile of 
OS (Table 3).  
The time to event OS analysis included all 36 patients, 34 died and 2 were 
censored. The median OS was superior in those with presence of DDR gene mutations 
as compared to those without these mutations (14 vs. 5 months, respectively) although 
this association failed to reach statistical significance (HR 0.58, 95% CI 0.29-1.14, 
p=0.08; Figure 1). However, the multivariable Cox regression model showed a 
significant improvement in OS in PDAC patients with DDR gene mutations as compared 
to those without these mutations (adjusted HR 0.37, 95% CI 0.15-0.94, p = 0.04; Table 
3). None of the other covariates were significantly associated with OS although body/tail 
pancreatic tumors had a near significant lower hazard of OS compared to head of 
pancreas tumors (adjusted HR 0.24, 95% CI 0.05-1.22, p=0.08; Table 3).  
The median ‘OS from surgery’ was not significantly different between those with 
presence of DDR gene mutations as compared to those without these mutations (23 vs. 
18.5 months, respectively; Log-Rank p = 0.94). 
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BRCA1/2 Gene Mutations and Overall Survival 
Bivariate logistic regression showed significantly higher odds of being in the 
highest quartile of OS with the presence of BRCA1/2 mutations (OR 1.56, 95% CI 1.17-
2.08, p = 0.004). This association remained significant after adjusting for other potential 
prognostic variables in a multivariate logistic regression model (AOR 1.77, 95% CI 1.26-
2.46, p = 0.003; Table 4). None of the other covariates were significantly associated 
with highest quartile of OS in the multivariate analysis (Table 4).  
Similarly, Kaplan Meier analysis showed a superior median OS in those with 
BRCA1/2 mutations as compared to those without these mutations (15 vs. 5 months), 
however this association was not statistically significant (HR 0.64, 95% CI 0.32-1.29, 
p=0.17; Figure 2). Interestingly, the multivariable Cox regression model showed a 
significant improvement in OS with the presence of BRCA1/2 mutations (adjusted HR 
0.32, 95% CI 0.11-0.94, p = 0.04; Table 4). Pathological nodal involvement (adjusted 
HR 3.48, 95% CI 1.06-11.39, p = 0.04) was significantly associated with higher hazard 
of dying from PDAC, although male gender (adjusted HR 0.42, 95% CI 0.15-1.20, p = 
0.10), location of primary tumor in body/tail (adjusted HR 0.21, 95% CI 0.04-1.03, p = 
0.05) were nearly significantly associated with lower hazard of dying from PDAC (Table 
4).  
Discussion 
In this study, we found that within a cohort of recurrent PDAC patients treated 
with FOLFIRINOX, those with presence of DDR gene mutations (germline and somatic) 
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have significantly longer OS compared to those without mutations in DDR genes. We 
also found that the presence of germline BRCA1/2 mutations was associated with 
longer OS in PDAC patients treated with FOLFIRINOX. Deleterious germline mutations 
in the absence of significant family history has been established as a risk factor and 
potential therapeutic target for PDAC15; however, the effect of both germline and 
somatic DDR gene mutations on the OS in PDAC patients treated with FOLFIRINOX 
has not been well known. Additionally, our study also validates the association of 
germline BRCA1/2 mutations and sensitivity to platinum-based chemotherapy reported 
by others in PDAC patients16, 17 and expands the hypothesis beyond germline BRCA1/2 
mutations to both somatic and germline mutation in DDR genes. Notably, our results of 
improved OS with platinum-based chemotherapy in patients with germline BRCA1/2 
mutations are similar to those reported by other large multi-institutional studies16. 
DDR gene mutations play an important role in double stranded DNA damage 
repair via homologous recombination, and defects in these genes may predict response 
to platinum-based chemotherapy16, 18, 19. Platinum compounds cause intercalation of the 
DNA and distortion of the DNA-helix20 which requires an intact dsDNA repair apparatus 
for restoration. DDR-impaired tumors are therefore sensitive to platinum-based 
chemotherapy. Specifically, germline BRCA mutations have been shown to predict 
response to platinum-based chemotherapy in breast and ovarian cancers18, 21.  
Precision treatment strategies are an attempt to exploit tumor-specific mutations such 
as those seen in DDR genes22. However, this is a developing area and not much is 
known about molecular subtypes in PDAC as opposed to other cancers such as breast, 
colon, gastric, bladder and lung where molecular subtypes have been well defined23-27. 
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Notably, these cancer subtypes have been found to have specific therapeutic targets 
and have shown to respond differently to anti-cancer drugs25, 28-30. To our knowledge 
there is only one large study that has classified PDAC into 4 subtypes based on the 
genomic alterations: stable, locally rearranged, scattered and unstable, and has shown 
good response to platinum-based chemotherapy in patients with unstable subtype 
and/or high BRCA mutational signature17. Our study is notable for having a significantly 
larger number of patients to better explore this association. 
The overall DDR gene mutation frequency in our cohort was 33.3% which is 
clearly higher than what was found in other next generation sequencing studies31, 32. For 
instance, Peterson et al found germline DDR gene mutations in 12% of patients with 
familial PDAC. In high-risk groups (Ashkenazi Jewish), mutation prevalence of up to 
17% has been reported33. This difference in DDR gene mutation prevalence might be 
due to the selection of different gene panels in different studies and lack of inclusion of 
both somatic and germline mutation in other studies. Despite the higher prevalence of 
DDR gene mutations, the genes that were found to be mutated in our study (BRCA1, 
BRCA2, PALB2, MSH2 and FANCF) were not different from those reported in other 
studies (BRCA1, BRCA2, PALB2, MSH2, MLH1 and MSH6). Of note, we excluded ATM 
gene mutations (seen in 2 patients) in our analysis as the emerging data suggests that 
ATM gene mutations does not contribute to homologous recombination DNA repair34.  
The results of our study are not definitive, but are hypothesis-generating. Clinical 
application of these results will require prospective validation of our results where 
specific DDR gene mutations are targeted with specific compounds. Interestingly, 
immunotherapy with anti-programmed death 1 antibody is one such strategy that is now 
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approved for the treatment of PDAC patients with microsatellite instability35. Similarly, 
clinical trials of poly ADP ribose polymerase (PARP) inhibitors have shown positive 
results in ovarian cancer patients with non-germline BRCA-mutated tumors36, 37 and the 
studies are ongoing in PDAC. In a recent phase I clinical trial in PDAC patients, olaparib 
(PARP inhibitor) added to irinotecan, cisplatin, and mitomycin C showed durable clinical 
responses however due to substantial toxicity the combination was considered 
unacceptable for further development38. In another phase II trial, rucaparib (PARP 
inhibitor) as a single agent has shown to have 11% objective response rate in patients 
with advanced PDAC who have received 1–2 prior chemotherapies. There are several 
other clinical trials (NCT01585805, NCT01489865, NCT01989546) including a phase III, 
randomized controlled trial (NCT02184195) that are currently ongoing to assess the role 
of PARP inhibitors in PDAC patients with germline or somatic BRCA mutations. 
Additionally, trials are also ongoing to assess the effect of ATR inhibitors alone 
(NCT02223923, NCT02264678, NCT02630199) or in combination with PARP inhibitors 
(NCT02723864) in solid tumors.  
There are several strengths of our study. First, we restricted testing to patients 
who had previously undergone surgery.  This allowed for adequate tissue for analysis in 
the vast majority of patients.  Lack of available tissue is a major barrier to carrying out 
translational research in pancreatic cancer.  Second, we utilized a high-quality, well-
annotated clinical database.  Third, we tested the hypothesis of association between 
germline and somatic DDR gene mutations and OS as well as BRCA1/2 gene mutations 
and OS in PDAC patients.  
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Together with the strengths of our study, there are several potential limitations. 
First, although we used a well-annotated and manually curated database and controlled 
for multiple potential confounders, our results might have been affected by residual 
confounding due to the retrospective nature, relatively small and single institution 
cohort. Second, our cohort was limited to only patients with initially localized disease 
who underwent surgical resection excluding a large proportion of PDAC patients with 
initially locally advance or metastatic disease potentially having an aggressive biology 
thereby raising a possibility of selection bias. Third, we were unable to control for 
comorbidities and other competing risks of mortality which might have affected our 
results. However, since FOLFIRINOX is indicated for relatively healthier PDAC patients 
with good performance status we do not think that the difference in comorbidities are 
the only explanation of our results. Fourth, we were unable to gather detailed family 
history of cancer due to the retrospective nature of this study. However, positive family 
history of cancer was noted in 51.4% of patients and we controlled for family history of 
cancer in our multivariate models. Fifth, since we could not analyze for progression free 
survival, we cannot say for sure that our results are due to finding a better prognostic 
group rather than being more sensitive to FOLFIRINOX per se. However, we did not 
notice any significant difference between the patients with and without DDR gene 
mutation while analyzing for ‘OS from surgery’.  
Lastly, we acknowledge that the median OS of our cohort is relatively lower than 
expected for a de novo metastatic population, but there are relatively few reports of 
survival in the post-surgical recurrence setting.  Our own internal data suggest it is 
shorter than that seen in studies of mostly newly diagnosed patients. Another possible 
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reason could be lack of second-line chemotherapy. In our cohort, 15 patients did not 
receive any second-line chemotherapy. Of those who received second-line 
chemotherapy, 8 patients received gemcitabine and nab-paclitaxel and the rest received 
mostly single agent chemotherapy with gemcitabine or capecitabine alone. In fact, many 
patients who were started on FOLFIRINOX were later reduced to FOLFOX or XELOX. 
Impaired tolerance to FOLFIRINOX and lack of or ineffective second-line chemotherapy 
probably explains the relatively lower poor median OS.  
In a small, single institution, retrospective study, we found that the presence of 
DDR gene mutations (germline and/or somatic) as well as germline BRCA1/2 mutations 
are associated with improved OS in PDAC patients treated with FOLFIRINOX. These 
results validate the association of germline BRCA1/2 mutations and platinum sensitivity 
reported by others in PDAC patients16, 17 and expands the hypothesis beyond germline 
BRCA1/2 mutations to both somatic and germline mutation in DDR genes which needs 
to be further tested in a larger study.  
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Figure 1: Kaplan Meier Curve in patients with and without mutations in Germline 
and Somatic DNA Damage Repair (DDR) Genes. 
Figure 2: Kaplan Meier Curve in patients with and without mutations in BRCA1/2 
Genes. 
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Table 1: Baseline characteristics of patients. 
Variable Overall 
Cohort 
N=36 
Germline and Somatic DDR Genes P-value*
Mutation 
Absent 
N= 24 (66.7%) 
Mutation 
Present N=12 
(33.3%) 
Age (years) 0.002 
       Median (Range) 65.5 (45.1-82.7) 66.0 (45.1-82.7) 64.6 (45.7-74.8) 
Gender 0.28 
       Male 21 (58.3) 16 (66.7) 5 (41.7) 
       Female 15 (41.7) 8 (33.3) 7 (58.3) 
Race, N (%) 0.72 
        White 35 (97.2) 24 (100) 11 (91.7) 
        African American 1 (2.8) 0 1 (8.3) 
CA 19-9, U/ml 0.68 
       Normal  9 (25.0) 5 (20.8) 4 (33.3) 
       Elevated 27 (75.0) 19 (79.2) 8 (66.7) 
Family history of cancer, N 
(%) 
1 
        No 17 (48.6) 12 (50.0) 5 (45.5) 
        Yes 18 (51.4) 12 (50.0) 6 (54.5) 
Location of Primary tumor (%) 0.85 
        Head 32 (88.9) 22 (91.7) 10 (83.3) 
        Body and Tail 4 (11.1) 2 (8.3) 2 (16.7) 
Tobacco Use (%) 0.28 
        No 15 (48.7) 12 (50.0) 3 (25.0) 
        Yes 21 (58.3) 12 (50.0) 9 (75.0) 
BMI (kg/m2) 0.39 
        ≤24.9 18 (50.0) 13 (54.2) 5 (41.7) 
       24.9-29.9 13 (36.1) 9 (37.5) 4 (33.3) 
       ≥30 5 (13.9) 2 (8.3) 3 (25.0) 
Jaundice at Presentation (%) 0.90 
        No 14 (38.8) 10 (41.7) 4 (33.3) 
        Yes 22 (61.1) 14 (58.3) 8 (66.7) 
Diabetes at Presentation (%) 1 
        No 23 (63.9) 15 (62.5) 8 (66.7) 
        Yes 13 (36.1) 9 (37.5) 4 (33.3) 
Surgery, N (%) 36 (100) 24 (66.7) 12 (33.3) NR 
Adjuvant Gemcitabine, N (%) 0.86 
        No 5 (13.9) 4 (16.7) 1 (8.3) 
        Yes 31 (86.1) 20 (83.3) 11 (91.7) 
Pathological T stage, N (%) 0.35 
       T1 and T2  4 (11.1) 3 (12.5) 1 (8.3) 
       T3  32 (88.9) 21 (87.5) 11 (91.7) 
Pathological N stage, N (%) 0.39 
       N0 5 (13.9) 2 (8.3) 3 (25.0) 
       N1 31 (86.1) 22 (91.7) 9 (75.0) 
Surgery, N (%) 1 
        R0 (Negative Margin) 29 (80.5) 19 (79.2) 10 (83.3) 
        R1 (Positive Margin) 7 (19.5) 5 (20.8) 2 (16.7) 
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Abbreviations: DDR, DNA damage repair; N, number; ULN, upper limit of normal; NR, not 
reported; CA, carbohydrate antigen; T, tumor; N, node; R0, negative margin; R1, microscopic 
positive margin; BMI, body mass index; * Calculated by chi-square except t-test for age.  
Table 2: Mutations seen in DNA damage repair genes in 12 patients (ID) of our cohort and 
their predicted functional significance.  
ID Gene Chromosome 
Position 
dbSNP ID Function Amino 
Acid 
Change 
SIFT 
function 
prediction 
PolyPhen-2 
function 
prediction 
1 BRCA1 17:41246481 rs1799950 Missense p.Q356R;
p.Q309R
Damaging Probably 
Damaging 
2 BRCA1 17:41199716 rs80356920 Missense
; Stop 
gain 
p.C675*;
p.V700D;
p.V1757D;
p.V1825D;
p.V1804D
Tolerated Benign 
BRCA1 17:41246481 rs1799950 Missense p.Q356R;
p.Q309R
Damaging Probably 
Damaging 
3 BRCA1 17:41222975 rs1799967 Missense p.M548I;
p.M1673I;
p.M1652I;
p.M1605I
Tolerated Benign 
BRCA2 13:32914755 rs767567428 Missense p.T2088I Damaging Benign 
4 BRCA2 13:32911295 rs28897716 Missense p.D935N Tolerated Benign 
5 BRCA1 17:41246061 rs28897677 Missense p.R496H;
p.R449H
Tolerated Benign 
6 BRCA1 17:41244429 rs4986852 Missense p.S993N;
p.S1040N
Tolerated Benign 
BRCA2 13:32972626 rs11571833 Stop gain p.K3326* N/A N/A 
7 BRCA1 17:41246481 rs1799950 Missense p.Q356R;
p.Q309R
Damaging Probably 
Damaging 
PALB2 16:23646857 rs45494092 Stop gain p.L337S Tolerated Benign 
8 BRCA1 17:41222975 rs1799967 Missense p.M548I;
p.M1673I;
p.M1652I;
p.M1605I
Tolerated Benign 
BRCA2 13:32912750 rs28897727 Missense p.D1420Y Damaging Benign 
9 BRCA2 13:32945172 rs11571747 Missense p.E2856A Tolerated Probably 
Damaging 
10 PALB2 16:23646857 rs45494092 Missense p.L337S Tolerated Benign 
11 PALB2 16:23634293 rs45551636 Missense p.G998E Damaging Probably 
Damaging 
PALB2 16:23641461 rs45532440 Missense p.E672Q Tolerated Benign 
12 MSH2 2:47403319 rs17217723 Missense Y43C Intolerant Probably 
damaging 
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Table 3: Multivariate logistic and Cox regression analyses of Somatic and Germline DDR 
Mutations genes. 
Variable Logistic Regression Cox regression 
AOR (95% CI) P-Value Adjusted HR P-value
Somatic and Germline DDR 
Mutations 
      Absent  1 (reference) 1 (reference) 
      Present 1.47 (1.04-2.06) 0.05 0.37 (0.15-0.94) 0.04 
Gender 
      Female 1 (reference) 1 (reference) 
      Male 1.27 (0.85-1.89) 0.26 0.50 (0.18-1.37) 0.18 
Age at Diagnosis 0.99 (0.97-1.00)  0.18 1.04 (0.99-1.10)  0.15 
Primary tumor site 
      Head 1 (reference) 1 (reference) 
      Body/Tail 1.29 (0.78-2.11) 0.33 0.24 (0.05-1.22) 0.08 
Family history of cancer, N 
(%) 
        No 1 (reference) 1 (reference) 
        Yes 1.03 (0.74-1.42) 0.87 1.29 (0.51-3.25) 0.59 
Pathological T Stage 
      T1/T2 1 (reference) 1 (reference) 
      T3 1.10 (0.65-1.86) 0.72 0.71 (0.13-3.75) 0.69 
Pathological N Stage 
      N0 1 (reference) 1 (reference) 
      N1 1.00 (0.63-1.58) 0.99  2.21 (0.67-7.25) 0.19 
Margin Involvement 
      No 1 (reference) 1 (reference) 
      Yes 0.88 (0.58-1.30) 0.52 1.73 (0.59-5.04) 0.32 
CA 19-9, U/ml 
       Normal  1 (reference) 1 (reference) 
       Elevated 1.05 (0.72-1.52) 0.82 1.95 (0.64-5.93) 0.24 
Adjuvant Chemotherapy 
      No 1 (reference) 1 (reference) 
      Yes 1.04 (0.66-1.63) 0.87 0.53 (0.14-2.05) 0.47 
Abbreviations: AOR, adjusted odds ratio; HR, hazard ratio; T, tumor; N, node; R0, negative 
margin; R1, microscopic positive margin; BMI, body mass index; CA, carbohydrate antigen; 
ULN, upper limit of normal. 
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Table 4: Multivariate logistic and Cox regression analyses of BRCA1/2 genes. 
Variable Logistic Regression Cox regression 
AOR (95% CI) P-Value Adjusted HR P-value
BRCA1/2 Mutations 
      Absent  1 (reference) 1 (reference) 
      Present 1.77 (1.26-2.46) 0.003 0.32 (0.11-0.94) 0.04 
Gender 
      Female 1 (reference) 1 (reference) 
      Male 1.36 (0.95-1.97) 0.11 0.42 (0.15-1.20) 0.10 
Age at Diagnosis 0.99 (0.97-1.00)  0.20 1.04 (0.99-1.10)  0.12 
Primary tumor site 
      Head 1 (reference) 1 (reference) 
      Body/Tail 1.39 (0.89-2.17) 0.16 0.21 (0.04-1.03) 0.05 
Family history of cancer, N (%) 
        No 1 (reference) 1 (reference) 
        Yes 1.07 (0.79-1.44) 0.66 1.10 (0.44-2.75) 0.84 
Pathological T Stage 
      T1/T2 1 (reference) 1 (reference) 
      T3 0.98 (0.61-1.59) 0.95 0.85 (0.18-4.09) 0.84 
Pathological N Stage 
      N0 1 (reference) 1 (reference) 
      N1 0.86 (0.58-1.29) 0.47  3.48 (1.06-11.39) 0.04 
Margin Involvement 
      No 1 (reference) 1 (reference) 
      Yes 0.90 (0.63-1.29) 0.58 1.66 (0.58-4.75) 0.34 
CA 19-9, U/ml 
       Normal  1 (reference) 1 (reference) 
       Elevated 0.96 (0.68-1.35) 0.82 2.15 (0.71-6.48) 0.17 
Adjuvant Chemotherapy 
      No 1 (reference) 1 (reference) 
      Yes 1.04 (0.69-1.57) 0.85 0.63 (0.17-2.31) 0.49 
Abbreviations: AOR, adjusted odds ratio; HR, hazard ratio; T, tumor; N, node; R0, negative 
margin; R1, microscopic positive margin; BMI, body mass index; CA, carbohydrate antigen; 
ULN, upper limit of normal. 
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